Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression

American Journal of Hematology

Volumn 88, Issue 11, 2013, Pages

  Wu, Shang Ju ^a   Tang, Jih Luh ^a   Lin, Chien Ting ^a   Kuo, Yuan Yeh ^b   Li, Li Yu ^b   Tseng, Mei Hsuan ^a   Huang, Chi Fei ^a   Lai, Yen Jun ^a   Lee, Fen Yu ^a   Liu, Ming Chih ^a   Liu, Chia Wen ^a   Hou, Hsin An ^a   Chen, Chien Yuan ^a   Chou, Wen Chien ^a   Yao, Ming ^a   Huang, Shang Yi ^a   Ko, Bor Sheng ^a   Tsay, Woei ^a   Tien, Hwei Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE 3A; JANUS KINASE 2; TRANSCRIPTION FACTOR RUNX1;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; CORRELATIONAL STUDY; DISEASE COURSE; EXON; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC STABILITY; GENETIC TRANSFORMATION; GROUPS BY AGE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MUTATION RATE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; RISK ASSESSMENT; RISK FACTOR; TIME TO LEUKEMIA TRANSFORMATION; U2AF1 GENE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PROGNOSIS; RIBONUCLEOPROTEINS; SURVIVAL ANALYSIS; TAIWAN; YOUNG ADULT;

EID: 84886257256     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23541     Document Type: Article

References (38)

1. Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011;29:504-515.
2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885.
3. Shih AH, Levine RL. Molecular biology of myelodysplastic syndromes. Semin Oncol 2011;38:613-620.
4. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: Implications for therapy. Semin Hematol 2008;45:39-48.
5. Chamuleau ME, Westers TM, van Dreunen L, et al. Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 2009;94:496-506.
6. Ishibashi M, Tamura H, Ogata K. Disease progression mechanism in myelodysplastic syndromes: Insight into the role of the microenvironment. Leuk Res 2011;35:1449-1452.
7. Raaijmakers MH. Myelodysplastic syndromes: Revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int J Hematol 2012;95:17-25.
8. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
9. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011;365:1384-1395.
10. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012;44:53-57.
11. Visconte V, Makishima H, Maciejewski JP, Tiu RV. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders. Leukemia 2012;26:2447-2454.
12. Wahl MC, Will CL, Luhrmann R. The spliceosome: Design principles of a dynamic RNP machine. Cell 2009;136:701-718.
13. Chen M, Manley JL. Mechanisms of alternative splicing regulation: Insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009;10:741-754.
14. Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012;119:3203-3210.
15. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119:3578-3584.
16. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012;119:3211-3218.
17. Wu SJ, Kuo YY, Hou HA, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012;120:3106-3111.
18. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013;88:201-206.
19. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: Clinical associations and prognostic implications. Leukemia 2012;26:1137-1140.
20. Hirabayashi S, Flotho C, Moetter J, et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood 2012;119:e96-e99.
21. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569-572.
22. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2011;26:542-545.
23. Lalioti MD, Gos A, Green MR, et al. The gene for human U2 snRNP auxiliary factor small 35-kDa subunit (U2AF1) maps to the progressive myoclonus epilepsy (EPM1) critical region on chromosome 21q22.3. Genomics 1996;33:298-300.
24. Kalcheva I, Plass C, Sait S, et al. Comparative mapping of the imprinted U2afbpL gene on mouse chromosome 11 and human chromosome 5. Cytogenet Cell Genet 1995;68:19-24.
25. Qian J, Yao DM, Lin J, et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PloS One 2012;7:e45760.
26. Swerdlow SH, Campo E, Hasrris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th ed. Lyon: IARC; 2008. pp 87-107.
27. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010;115:2749-2754.
28. Chou WC, Lei WC, Ko BS, et al The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011;25:246-253.
29. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
30. Shiah HS, Kuo YY, Tang JL, et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia 2002;16:196-202.
31. Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome-The mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007;139:405-414.
32. Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005;11:1372-1379.
33. Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010;115:5222-5231.
34. Chen CY, Lin LI, Tang JL, et al. Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 2006;20:1155-1158.
35. Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2011;116:4086-4094.
36. Hou HA, Kuo YY, Liu CY, et al. DNMT3A mutations in acute myeloid leukemia: Stability during disease evolution and clinical implications. Blood 2012;119:559-568.
37. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-726.
38. Tien HF, Wang CH, Chuang SM, et al. Acute leukemic transformation of myelodysplastic syndrome-Immunophenotypic, genotypic, and cytogenetic studies. Leuk Res 1995;19:595-603.